Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases.

Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Murata Y, Takasugi K.

Mod Rheumatol. 2014 Jan;24(1):137-43. doi: 10.3109/14397595.2013.854048.

PMID:
24261770
2.

Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.

Hakala M, Immonen K, Korpela M, Vasala M, Kauppi MJ.

Ann Rheum Dis. 2013 Mar;72(3):464-5. doi: 10.1136/annrheumdis-2012-202156. Epub 2012 Nov 12. No abstract available.

PMID:
23148310
3.

AA amyloidosis treated with tocilizumab: case series and updated literature review.

Courties A, Grateau G, Philippe P, Flipo RM, Astudillo L, Aubry-Rozier B, Fabreguet I, Fahd W, Fain O, Guggenbuhl P, Hachulla E, Papo T, Richez C, Sibilia J, Morel J, Berenbaum F, Sellam J; Club Rhumatismes Inflammation and the REGATE Registry.

Amyloid. 2015;22(2):84-92. doi: 10.3109/13506129.2014.1002031. Epub 2015 Jan 14. Review.

PMID:
25585627
4.

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2014 May;24(3):405-9. doi: 10.3109/14397595.2013.844294. Epub 2013 Oct 21.

PMID:
24252016
5.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
6.

Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X.

Arthritis Rheum. 2003 Jul;48(7):2019-24.

7.

Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.

Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S46-53. Epub 2015 Jun 29. Review.

PMID:
26120866
8.

Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.

Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske AE, Hellmann P, Gaubitz M.

Clin Rheumatol. 2015 Apr;34(4):673-81. doi: 10.1007/s10067-015-2879-0. Epub 2015 Jan 29.

9.
10.
12.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
13.

Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases.

Fernández-Nebro A, Olivé A, Castro MC, Varela AH, Riera E, Irigoyen MV, García de Yébenes MJ, García-Vicuña R.

Am J Med. 2010 May;123(5):454-61. doi: 10.1016/j.amjmed.2009.11.010.

PMID:
20399323
14.

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.

Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16.

PMID:
25231180
15.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
16.

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.

Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, Shi K, Narazaki M, Hagihara K, Tomita T, Yoshikawa H, Tanaka T, Kumanogoh A.

Scand J Rheumatol. 2013;42(4):253-9. doi: 10.3109/03009742.2012.762037. Epub 2013 Mar 7.

PMID:
23470089
17.

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.

Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N.

Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26.

PMID:
23099471
18.

The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.

Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.

Ann Rheum Dis. 2008 May;67(5):710-2. Epub 2007 Dec 13.

PMID:
18079191
19.

[Amyloidosis in rheumatic diseases].

Zdrojewski Z.

Ann Acad Med Stetin. 2010;56 Suppl 1:7-15. Review. Polish.

PMID:
21365934
20.

[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].

Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL.

Ter Arkh. 2013;85(5):24-9. Russian.

PMID:
23819335

Supplemental Content

Support Center